Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the effects of the interleukin-2 given in
combination with pembrolizumab.
Interleukin-2 (IL-2) is also called aldesleukin, or Proleukin™.
Pembrolizumab is also called Keytruda™, or anti-PD-1 antibody.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute